Cannabinoid receptor-1 antagonism: a new perspective on treating a murine schistosomal liver fibrosis model

Intake, nutrient digestibility, rumen parameters, growth rate, carcase characteristics and cannabinoid residues of sheep fed pelleted rations containing hemp (Cannabis sativa L.) stubble

The feeding value and impact of hemp stubble in the diet of ruminants is unknown. Fifteen Merino castrated male sheep were maintained in individual pens and fed one of three pelletized experimental inclusion diets, as a 0% (Control), 28% (Hemp 1), and 56% (Hemp 2) pellet that delivered a diet meeting the nutrient requirements of the animals. Inclusion of hemp stubble had no effect (P > 0.05) on either DM intake, live weight gain or the feed to gain ratio but positively impacted (P < 0.05) on nutrient digestibility. Hemp stubble inclusion increased the concentration (but not molar proportions) of acetic and butyric acids and increased both the concentrations and molar proportions of iso-butyric, iso-valeric, hexanoic and heptanoic acids, possibly due to increased protein digestibility and/or changes in the composition of rumen cellulolytic bacteria. Tetrahydrocannabinolic acid (THCA) was the only cannabinoid found in plasma in the sheep fed the hemp-containing diets, and this was found at very low concentrations (<16 μg/L). The psychoactive cannabinoid delta-9-tetrahydrocannabinol (Δ ⁹-THC) was not detected in any plasma samples. THCA was detected in the liver of two sheep fed the Hemp 1 pellets and two sheep fed the Hemp 2 pellets. Cannabidiol (CBD) was detected in the liver of one sheep fed the Hemp 2 pellets (but no liver THCA was detected in this sheep). Δ ⁹-THC was detected in both the kidney fat and subcutaneous fat of all sheep fed hemp stubble, with the concentrations being higher (P < 0.05) in the sheep fed the Hemp 1 pellets. THCA was also detected in the subcutaneous fat of one of the sheep fed the Hemp 1 pellets. Four of the five sheep fed the Hemp 1 pellet and one of the five sheep fed Hemp 2 pellet had detectable levels of Δ ⁹-THC in the meat (loin). No other cannabinoids were detected in the meat. Current food standards regulations in Australia prohibit presence of any cannabinoid residues in commercial meat products; thus, determination of a withholding period is required to enable the safe feeding of hemp-stubble to sheep. Further research is also required to gain a greater understanding of the rumen metabolism of cannabinoids.

Reversine and herbal Xiang-Sha-Liu-Jun-Zi decoction ameliorate thioacetamide-induced hepatic injury by regulating the RelA/NF-κB/caspase signaling pathway

This study investigated the anti-fibrotic effects of reversine and Chinese medicine Xiang–Sha–Liu–Jun–Zi decoction (XSLJZD) on thioacetamide (TAA)-induced hepatic injury. Sprague-Dawley rats were intraperitoneally administered with TAA, then injected with reversine intraperitoneally, and/or orally provided with XSLJZD. TAA resulted in liver injury with increases in the liver index and levels of serum aspartate aminotransferase (AST) and alanine aminotransferase. Reversine alleviated the liver index and AST level and improved TAA-induced pathological changes but decreased TAA-induced collagen deposition, and α-smooth muscle actin and transforming growth factor-β1 expression. Reversine also modulated the mRNA levels of inflammatory cytokines, such as RelA, interleukin (IL)-17A, IL-22, IL-1β, IL-6, NLR family pyrin domain containing 3, platelet-derived growth factor, and monocyte chemoattractant protein, and suppressed nuclear factor (NF)-κB (p65) phosphorylation and caspase 1 activation. Meanwhile, XSLJZD protected TAA-injured liver without increasing fibrosis and enhanced the regulating effect of reversine on RelA, IL-17A, IL-1β, and MCP-1 cytokines. In conclusion, reversine ameliorates liver injury and inhibits inflammation reaction by regulating NF-κB, and XSLJZD protects the liver through its synergistic effect with reversine on regulating inflammatory cytokines.

Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?

The incidence rate and mortality of liver fibrosis caused by various etiologies are high throughout the world. Liver fibrosis, the subsequent cirrhosis and other serious related complications threaten the health of patients and represent a serious medical burden; yet, there is still a lack of approved methods to prevent or reverse liver fibrosis. Therefore, effective hepatic antifibrotic drugs are urgently needed. The activation and proliferation of hepatic stellate cells are still the mechanisms of fibrosis that remain the focus of therapeutic research. In recent years, significant progress has been made in the development and applicability of antifibrosis drugs. In this review, we summarize the effectiveness and safety of available antifibrosis drugs utilizing different targets. In addition, some characteristics of antifibrosis drugs in phase II and III trials are introduced in detail.